Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pharmacokinetics and blood pressure response of losartan in end-stage renal disease
Autore:
Sica, DA; Halstenson, CE; Gehr, TWB; Keane, WF;
Indirizzi:
Virginia Commonwealth Univ, Div Clin Pharmacol & Hypertens, Med Coll Virginia, Richmond, VA 23298 USA Virginia Commonwealth Univ Richmond VA USA 23298 , Richmond, VA 23298 USA Virginia Commonwealth Univ, Dept Nephrol, Med Coll Virginia, Richmond, VA 23298 USA Virginia Commonwealth Univ Richmond VA USA 23298 , Richmond, VA 23298 USA Hennepin Cty Med Ctr, Div Nephrol, Drug Evaluat Unit, Minneapolis, MN 55415 USA Hennepin Cty Med Ctr Minneapolis MN USA 55415 , Minneapolis, MN 55415 USA
Titolo Testata:
CLINICAL PHARMACOKINETICS
fascicolo: 6, volume: 38, anno: 2000,
pagine: 519 - 526
SICI:
0312-5963(200006)38:6<519:PABPRO>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
II RECEPTOR ANTAGONIST; ACTIVE METABOLITE EXP3174; ANGIOTENSIN-II; ANAPHYLACTOID REACTIONS; ESSENTIAL-HYPERTENSION; HEALTHY-SUBJECTS; AN69 MEMBRANES; HUMAN PLASMA; HEMODIALYSIS; INSUFFICIENCY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
34
Recensione:
Indirizzi per estratti:
Indirizzo: Sica, DA Virginia Commonwealth Univ, Div Clin Pharmacol & Hypertens, Med Coll Virginia, Box 980160,MCV Stn, Richmond, VA 23298 USA Virginia Commonwealth Univ Box 980160,MCV Stn Richmond VA USA 23298
Citazione:
D.A. Sica et al., "Pharmacokinetics and blood pressure response of losartan in end-stage renal disease", CLIN PHARMA, 38(6), 2000, pp. 519-526

Abstract

Background: Losartan is a selective angiotensin AT(1) receptor antagonist currently employed in the management of essential hypertension. This compound is in common use in populations with renal failure and end-stage nnal disease (ESRD). Objective: To investigate the pharmacokinetics and pharmacodynamics of losartan in patients with ESRD in order to establish administration guidelines. Methods: Patients were administered losartan 100 mg/day for 7 days, and after the seventh and final dose pharmacokinetic parameters were determined for both losartan and its active metabolite E-3174. During the study, the haemodialytic clearances of losartan and E-3174 were measured during a standard 4-hour dialysis session. Neurohumoral and biochemical changes were assessed during losartan administration. Results: The pharmacokinetics of losartan and E-3174 in haemodialysis patients did not alter to a clinically significant level. Losartan administration was accompanied by a decline in plasma aldosterone level as well as by an increase in plasma renin activity. Losartan administration resulted in a decline in plasma uric acid level, despite the fact that the study participants had no residual renal function. Losartan and E-3174 were not dialysable. Conclusions: The pharmacokinetics of losartan and E-3174 are minimally altered in ESRD; thus, dosage adjustment is not required in the presence of advanced dialysis-dependent renal failure. In addition, postdialysis supplementation is not required for losartan because of the negligible dialysability of losartan and E-3174.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/21 alle ore 04:20:17